134 related articles for article (PubMed ID: 28753594)
1. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.
Besse L; Kraus M; Besse A; Bader J; Silzle T; Mehrling T; Driessen C
Blood Cancer J; 2017 Jul; 7(7):e589. PubMed ID: 28753594
[No Abstract] [Full Text] [Related]
2. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
López-Iglesias AA; Herrero AB; Chesi M; San-Segundo L; González-Méndez L; Hernández-García S; Misiewicz-Krzeminska I; Quwaider D; Martín-Sánchez M; Primo D; Paíno T; Bergsagel PL; Mehrling T; González-Díaz M; San-Miguel JF; Mateos MV; Gutiérrez NC; Garayoa M; Ocio EM
J Hematol Oncol; 2017 Jun; 10(1):127. PubMed ID: 28633670
[TBL] [Abstract][Full Text] [Related]
3. A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
Jin J; Mao S; Li F; Li X; Huang X; Yu M; Guo W; Jin J
Med Oncol; 2019 Aug; 36(9):77. PubMed ID: 31372848
[TBL] [Abstract][Full Text] [Related]
4. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Díaz-Tejedor A; Rodríguez-Ubreva J; Ciudad L; Lorenzo-Mohamed M; González-Rodríguez M; Castellanos B; Sotolongo-Ravelo J; San-Segundo L; Corchete LA; González-Méndez L; Martín-Sánchez M; Mateos MV; Ocio EM; Garayoa M; Paíno T
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731936
[TBL] [Abstract][Full Text] [Related]
5. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Kikuchi S; Suzuki R; Ohguchi H; Yoshida Y; Lu D; Cottini F; Jakubikova J; Bianchi G; Harada T; Gorgun G; Tai YT; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2015 Sep; 29(9):1918-27. PubMed ID: 25801913
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.
Bhatia S; Krieger V; Groll M; Osko JD; Reßing N; Ahlert H; Borkhardt A; Kurz T; Christianson DW; Hauer J; Hansen FK
J Med Chem; 2018 Nov; 61(22):10299-10309. PubMed ID: 30365892
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
8. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
9. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Jagannath S; Dimopoulos MA; Lonial S
Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.
Mithraprabhu S; Khong T; Jones SS; Spencer A
Br J Haematol; 2013 Aug; 162(4):559-62. PubMed ID: 23692150
[No Abstract] [Full Text] [Related]
11. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
12. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Mandl-Weber S; Meinel FG; Jankowsky R; Oduncu F; Schmidmaier R; Baumann P
Br J Haematol; 2010 May; 149(4):518-28. PubMed ID: 20201941
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
14. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.
Smith EM; Zhang L; Walker BA; Davenport EL; Aronson LI; Krige D; Hooftman L; Drummond AH; Morgan GJ; Davies FE
Oncotarget; 2015 Jul; 6(19):17314-27. PubMed ID: 26015393
[TBL] [Abstract][Full Text] [Related]
15. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
[TBL] [Abstract][Full Text] [Related]
16. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
17. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
18. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
19. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
Harada T; Hideshima T; Anderson KC
Int J Hematol; 2016 Sep; 104(3):300-9. PubMed ID: 27099225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
